New skin treatment begins human safety testing
NCT ID NCT06193434
Summary
This early-stage study tested the safety and how the body processes a new drug called IBI356 for atopic dermatitis (eczema). Researchers gave the drug to 99 healthy volunteers and people with moderate-to-severe eczema to check for side effects and measure drug levels in the blood. The main goal was to determine safe dosage ranges before larger studies can test effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, 200443, China
Conditions
Explore the condition pages connected to this study.